The mercurial and Twitter-obsessed Tesla ($TSLA) CEO changed his handle overnight to "Elon Tusk" with an elephant emoji, and tweeted that there would be "some Tesla news" coming at 2 p.m. on Thursday.
A master of capturing media attention, Musk could be teasing a gimmicky Tesla feature, à la "Dog Mode," that would deflect some of the scrutiny he is once again under for tangling with the SEC over its regulatory practices. Or he could make a more serious announcement related to Model 3 production targets, or even how the company plans to pay off a $920 million convertible bond due on the first of the month.
The point is: no one knows ー and that's the problem. Earlier this week the SEC complained that Musk should be held in contempt for continuing to tweet market-moving investor information without prior sign-off from Tesla lawyers, which was part of Musk's settlement agreement with the agency.
That became infinitely more difficult when the company's general counsel quit last week after just two months.
Seth Schachner, Managing Director at Strat Americas, on Hollywood's latest blockbusters utilizing content creation. Plus, the future of YouTube and TikTok.
Ashley Gold, Axios' Tech/Policy reporter, discusses what the future of Google and search engines will look like after the tech giant faces an antitrust trial.
A labor rights group has alleged that Starbucks sourced coffee from a major Brazilian cooperative whose member farms were cited for keeping workers in slave-like conditions.
X, the social media platform owned by Trump adviser Elon Musk, is challenging the constitutionality of a Minnesota ban on using deepfakes to influence elections and harm candidates.
Seth Goldstein, Equity Strategist at Morningstar, breaks down Tesla's earnings report, talks Musk's future with the company and how stocks have responded.
Senior Health Correspondent for TIME, Alice Park, gives us a deeper look into how Eli Lilly's new pill orforglipron may change the healthcare industry.
